Fate Therapeutics Inc. (FATE)
0.77
0.01 (1.70%)
At close: Apr 02, 2025, 3:59 PM
0.77
0.08%
After-hours: Apr 02, 2025, 07:55 PM EDT
Fate Therapeutics Income Statement
Financials in USD. Fiscal year
is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
| Revenue | 13.63M | 63.53M | 96.3M | 55.85M | 31.43M | 10.68M | 4.74M | 4.11M | 4.4M | 2.43M | n/a | 971K | 2.67M | 1.17M |
| Cost of Revenue | n/a | 161.7M | 13.76M | 5.85M | 125.62M | 87.77M | 56.02M | 34.36M | 26.45M | 19.86M | 16.43M | 12.01M | 12M | n/a |
| Gross Profit | 13.63M | -98.16M | 82.54M | 50M | -94.19M | -77.09M | -51.28M | -30.25M | -22.05M | -17.43M | -16.43M | -11.04M | -9.33M | 1.17M |
| Operating Income | -210.28M | -190.51M | -308.39M | -216.99M | -128.09M | -100.73M | -67.09M | -42.13M | -31.96M | -27.78M | -24.9M | -17.68M | -13.56M | -13.29M |
| Interest Income | 17.29M | 17.19M | 5.84M | 1.31M | 2.4M | 4.33M | 2.19M | 559K | 138K | 10K | 2K | 6K | 1K | 2K |
| Pretax Income | -186.26M | -160.93M | -281.72M | -212.15M | -173.39M | -98.15M | -66.6M | -42.95M | -33.46M | -29.99M | -25.88M | -20.89M | -14.24M | -13.43M |
| Net Income | -186.26M | -160.93M | -255.06M | -206.3M | -170.3M | -97.71M | -66.6M | -42.95M | -33.46M | -29.99M | -25.88M | -20.89M | -14.24M | -13.43M |
| Selling & General & Admin | 74.17M | 79.45M | 84.23M | 57.32M | 33.9M | 23.64M | 15.81M | 11.87M | 9.91M | 10.35M | 8.47M | 6.64M | 4.23M | 4.61M |
| Research & Development | 135M | 172.6M | 320.45M | 215.52M | 125.62M | 87.77M | 56.02M | 34.36M | 26.45M | 19.86M | 16.43M | 12.01M | 12M | 9.86M |
| Other Expenses | 14.74M | n/a | 20.82M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 223.91M | 254.04M | 404.69M | 272.84M | 159.52M | 111.41M | 71.83M | 46.23M | 36.37M | 30.21M | 24.9M | 18.65M | 16.23M | 14.46M |
| Interest Expense | n/a | n/a | 5.84M | n/a | n/a | 1.75M | 1.7M | 1.27M | 1.64M | 2.22M | 549K | 796K | 487K | 127K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 223.91M | 254.04M | 404.69M | 272.84M | 159.52M | 111.41M | 71.83M | 46.23M | 36.37M | 30.21M | 24.9M | 18.65M | 16.23M | 14.46M |
| Income Tax | n/a | n/a | -26.66M | -5.85M | -3.09M | -441K | 2.19M | 297K | -743K | -677K | 53K | 796K | 487K | 127K |
| Shares Outstanding (Basic) | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M | 68.19M | 56.2M | 41.98M | 31.75M | 25.48M | 20.45M | 19.44M | 8.87M | 8.87M |
| Shares Outstanding (Diluted) | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M | 68.19M | 56.2M | 41.98M | 31.75M | 25.48M | 20.45M | 19.75M | 8.87M | 8.87M |
| EPS (Basic) | -1.64 | -1.64 | -2.63 | -2.18 | -2.07 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -1.07 | -1.61 | -1.51 |
| EPS (Diluted) | -1.64 | -1.64 | -2.63 | -2.18 | -2.07 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -1.06 | -1.61 | -1.51 |
| EBITDA | -176.58M | -172.23M | -294.63M | -211.14M | -125M | -94.2M | -63.7M | -40.71M | -30.94M | -27.09M | -24.41M | -19.53M | -13.16M | -12.63M |
| EBIT | -195.54M | -190.51M | -308.39M | -216.99M | -128.09M | -96.4M | -64.9M | -41.68M | -31.82M | -27.77M | -25.33M | -20.1M | -13.75M | -13.3M |
| Depreciation & Amortization | 18.96M | 18.28M | 13.76M | 5.85M | 3.09M | 2.19M | 1.2M | 971K | 881K | 687K | 496K | 571K | 590K | 672K |